Portfolio Lab

Krystal Biotech, Inc.

  • Stock
  • Ticker KRYS
  • ISIN US5011471027
  • Nasdaq

Health care · Biotechnology · USA

$308.89 −2.19%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Krystal Biotech, Inc. since 09/2017, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

KRYSGlobal equities (VT)

$10,000 grew to $61,667. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −53.4% in 11/2021, measured from the peak in 03/2021. It took 9 months to get back to the old peak.

1-year return
+51.2%
5-year return p.a.
+42.6%
Return p.a. since 09/2017
+44.4%
Volatility p.a.
51.5%
Largest decline
−53.4%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue91889698107116119127
Operating income4136394144545871
EBITDA4338414346556073
Net income4536387951565563
Earnings per share1.531.201.292.661.701.831.792.05
Balance sheet
Total assets1,0561,0741,1381,2401,3341,3971,5011,586
Liabilities1099098102114120142150
Equity9469851,0411,1381,2201,2771,3591,436
Cash345309354393496501428463
Cash flow
Operating cash flow5331534078807591
Capital expenditure-0.8-6.2-1.9-1.7-2.1-7.1-3.6-1.0
Free cash flow5225513875737190

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +166.5%, weakest 2020 at +8.3%. 8 of 8 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
2 Nov 2026$2.05
3 Aug 2026$1.79
4 May 2026$1.83
17 Feb 2026$1.70
3 Nov 2025$2.66
4 Aug 2025$1.29
6 May 2025$1.20
19 Feb 2025$1.53
4 Nov 2024$0.91
5 Aug 2024$0.53
6 May 2024$0.03
26 Feb 2024$0.31

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€8.3bn
Market cap in trading currency
$9.15bn
Enterprise value
$8.24bn
P/E
41.9
P/S
19.47
P/B
6.38
EV/Sales
17.53
EV/EBITDA
35.3
Earnings yield
2.4%
FCF yield
3.4%

Results (last four quarters)

Revenue
$470m
Gross profit
–
EBITDA
$234m
Net income
$225m
Earnings per share
$7.37
Revenue per share
$15.86
Revenue growth
+30.2%
Earnings growth
−20.5%

Profitability

Gross margin
–
Operating margin
48.4%
Net margin
47.9%
Return on equity
17.5%
Return on assets
14.2%

Balance sheet and cash flow

Cash
$912m
Cash per share
$30.77
Financial debt
–
Debt/equity %
–
Current ratio
7.89
Book value per share
$48.44
Operating cash flow
$324m
Free cash flow
$310m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
29.6m
Volume
286,633
Avg. volume 3 months
282,411
Relative volume
1.0

Price and technicals

Price
$308.89
1 day
−2.2%
52-week high
$378.15
52-week low
$204.23
Distance to 52-week high
−18.3%
Distance to 52-week low
+51.2%
Distance to 50-day line
−4.2%
Distance to 200-day line
−0.5%
RSI (14)
47
Volatility 1M
52.9%

Performance

1 week
+1.2%
1 month
−3.5%
3 months
−9.6%
6 months
+3.2%
YTD
+25.3%
1 year
+51.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has KRYS performed since 09/2017?

$10,000 grew to $290,310 by 20 Nov 2026, which is +44.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is KRYS?

Volatility was 51.5% per year, measured on monthly returns. The largest decline from a peak was −53.4%, with the low in 11/2021.

How does KRYS compare with a broad equity ETF?

Over the same period Global equities (VT) returned +10.1% per year at 15.7% volatility, KRYS returned +44.4% at 51.5%. The correlation of monthly returns was 0.23; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Krystal Biotech, Inc. (KRYS): Return and risk